Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

Endometrial Cancer - Advanced

Trial Name: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed By Carboplatin and Paclitaxel Vs. Carboplatin And Paclitaxel For Optimally Debulked, Advanced Endometrial Carcinoma.

Protocol ID: GOG-0258

Eligibility:

Eligible Patients
  • All patients with Surgical Stage III or IVA endometrial carcinoma, including clear cell and serous papillary and undifferentiated carcinomas.
  • Surgical Stage III disease includes those patients with positive adnexa, tumor invading the serosa, positive pelvic and/or para-aortic nodes, or vaginal involvement. Patients with positive pelvic washings as the only extra-uterine disease are eligible only if the histology is clear cell or serous papillary.
  • Surgical Stage IVA includes patients with bladder or bowel mucosal involvement, but no spread outside the pelvis.
  • Surgery must have included a hysterectomy and bilateral salpingo-oophorectomy. Pelvis lymph node sampling and para-aortic lymph node sampling are optional.
  • Patients must meet required laboratory values
  • Patients must be 18 years of age or older
Ineligible Patients
  • Patients with carcinosarcoma
  • Patients with recurrent endometrial cancer
  • Patients who have had pelvic or abdominal radiation therapy
  • Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of active malignancy within the last five years. Patients are also excluded if their previous cancer treatment contraindicates this protocol therapy.
  • Patients who have received prior chemotherapy for endometrial cancer.

Enrollment: • About 804 people will take part in this study at several medical centers.

Benefits:

Taking part in this study may or may not make your health better. While doctors hope radiation therapy and chemotherapy will be more useful against cancer compared to chemotherapy alone, there is no proof of this yet. We do know that the information from this study will help doctors learn more about cisplatin plus radiation therapy, followed by carboplatin and paclitaxel as a treatment for cancer.

Contact:

These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353.

Created: Jun 3, 2011

Updated: Jan 18, 2013

« Return to Trials